List of Excipients in Branded Drug CORLOPAM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	CORLOPAM	fenoldopam mesylate	0409-2304	ANHYDROUS CITRIC ACID
Hospira Inc	CORLOPAM	fenoldopam mesylate	0409-2304	PROPYLENE GLYCOL
Hospira Inc	CORLOPAM	fenoldopam mesylate	0409-2304	SODIUM METABISULFITE
Hospira Inc	CORLOPAM	fenoldopam mesylate	0409-2304	TRISODIUM CITRATE DIHYDRATE
Hospira Inc	CORLOPAM	fenoldopam mesylate	0409-2304	WATER

Corlopam Excipient Strategy and Commercial Opportunities for Fenoldopam Mesylate

Last updated: September 2, 2026

Corlopam is the U.S. brand for fenoldopam mesylate injection, an intravenous dopamine-1 receptor agonist approved for short-term blood-pressure reduction in hospitalized patients with severe hypertension. Its commercial opportunity is primarily an injectable reformulation and supply-reliability opportunity, not a conventional oral-generic opportunity. The most attractive products would reduce preparation steps, address sulfite sensitivity, improve container compatibility, and support emergency-department and intensive-care workflows.

What is Corlopam and how is it formulated?

Corlopam contains fenoldopam mesylate, a selective dopamine-1 receptor agonist administered by continuous intravenous infusion. The product is supplied as a concentrated injectable solution requiring dilution before administration.

Attribute	Corlopam profile
Active ingredient	Fenoldopam mesylate
Dosage form	Sterile intravenous injection
Clinical use	Short-term reduction of blood pressure in severe hypertension
Administration	Continuous intravenous infusion
Reference strength	10 mg/mL concentrate
Route	Intravenous
Primary formulation issue	Stability and compatibility of a concentrated, acidic injectable solution
Primary commercial issue	Hospital preparation burden and limited acute-care use
Generic pathway	Abbreviated New Drug Application, subject to product-specific FDA requirements
Biosimilar relevance	None; fenoldopam is a synthetic small molecule

The labeled product contains fenoldopam mesylate in an aqueous vehicle and sodium metabisulfite as an inactive ingredient. The reference labeling identifies sulfite sensitivity as a relevant safety consideration. Fenoldopam products are diluted before infusion in compatible intravenous solutions, including commonly used dextrose or sodium chloride solutions, under the applicable product labeling. [1,2]

What excipients are used in Corlopam?

The core Corlopam formulation uses a simple aqueous injectable system rather than a complex suspension, emulsion, depot system, or lyophilized presentation.

Reference formulation

Component	Function
Fenoldopam mesylate	Active pharmaceutical ingredient
Water for Injection	Solvent and injectable vehicle
Sodium metabisulfite	Antioxidant and oxygen-scavenging excipient
Acidic formulation environment	Supports chemical stability and solubility

Sodium metabisulfite is commercially important because it can reduce oxidative degradation of an oxidation-sensitive drug substance. Its use also creates a product-positioning limitation: sulfite-containing injections require labeling and clinical management for patients with known sulfite hypersensitivity, particularly patients with asthma who may be susceptible to sulfite reactions. [1]

The formulation is not protected commercially by excipient complexity. A competitor would likely focus on formulation performance, container closure, stability, administration convenience, and regulatory differentiation rather than attempting to reproduce the brand presentation exactly.

What excipient strategies could improve fenoldopam injection?

The strongest development programs would prioritize four objectives: oxidation control, sulfite reduction or elimination, administration convenience, and compatibility across hospital infusion systems.

Sulfite-free formulation

A sulfite-free fenoldopam injection would have the clearest clinical differentiation. Candidate antioxidant systems could include:

• Ascorbic acid or ascorbate salts
• Sodium thiosulfate
• Methionine
• Cysteine or other thiol-based systems
• Chelating agents such as edetate salts, if justified by compatibility and regulatory assessment
• Nitrogen-protected manufacturing and filling
• Low-oxygen headspace and oxygen-barrier packaging

Each alternative must be assessed for degradation products, pH drift, infusion-line compatibility, extractables and leachables, and toxicological acceptability. Replacing sodium metabisulfite is not a simple substitution because the antioxidant must remain effective during manufacturing, storage, dilution, and administration.

A sulfite-free product could be positioned for hospitals that want to avoid sulfite exposure or reduce medication-selection constraints in patients with documented sulfite sensitivity. That opportunity is clinically narrower than the total fenoldopam market but can support premium positioning if the formulation provides a measurable safety or workflow benefit.

Ready-to-use diluted infusion

The reference product is a concentrate. A ready-to-use infusion in a flexible bag or prefilled syringe could eliminate bedside dilution and reduce dosing errors.

Potential presentations include:

Presentation	Commercial use
Ready-to-use infusion bag	Intensive-care and emergency-department continuous infusion
Pharmacy-prepared syringe	Transport, procedural areas, and short-duration infusion
Single-dose vial with integrated dilution instructions	Lower-cost generic substitution
Dual-chamber container	Separation of drug and diluent until use
Concentrated vial in smaller fill volume	Reduced storage and waste

A ready-to-use bag would need validated stability after manufacture, during refrigerated and room-temperature storage, and after connection to infusion equipment. The development program would also need to evaluate adsorption to polyvinyl chloride and polyolefin tubing, filter compatibility, pump accuracy, and in-use stability.

Low-volume concentrated presentation

A more concentrated product could reduce fluid load in patients requiring strict volume management. That benefit is relevant in intensive-care settings, although increased concentration raises the importance of dosing accuracy, infusion-pump safeguards, and dilution instructions.

The commercial value depends on the achievable concentration without precipitation, excessive viscosity, pH instability, or increased local irritation risk. A higher-strength presentation could be protected through formulation and container-closure claims if the technical performance is difficult to reproduce.

Preservative-free unit-dose packaging

Fenoldopam is used intravenously in acute-care settings, where preservative-free single-use packaging is generally preferable. Multi-dose vials would create additional microbial-preservation and labeling requirements and are unlikely to offer a strong value proposition.

A unit-dose vial, prefilled syringe, or small infusion bag would better match hospital medication-safety practices. The most commercially useful packaging innovation may be a prefilled, barcode-ready presentation rather than a new excipient.

What patent and regulatory protections cover Corlopam?

Corlopam’s original small-molecule and formulation exclusivity are old relative to modern injectable product-development cycles. The practical protection for a new fenoldopam product would most likely come from regulatory exclusivity, formulation patents, manufacturing claims, device claims, and trade secrets rather than the original brand patent estate.

FDA approval and exclusivity

Corlopam was approved by the FDA in 1997 for short-term blood-pressure reduction in severe hypertension. Its approval predates current commercial interest in many hospital-ready injectable formats. The original new-drug exclusivity period has expired. Any remaining commercial value depends on product availability, hospital contracts, and the competitive status of fenoldopam injection products. [1,3]

For an ANDA applicant, the relevant issues would include:

• Reference-listed-drug designation
• Product-specific bioequivalence requirements
• Sterility and particulate controls
• Injectable product quality attributes
• Labeling and dilution instructions
• Paragraph IV certification against any listed patents
• FDA requirements for inactive ingredients in parenteral products

Because fenoldopam is administered intravenously, conventional oral bioequivalence methods are not the central issue. The applicant must demonstrate pharmaceutical equivalence and comply with injectable-product chemistry, manufacturing, and controls requirements. The FDA may require comparative physicochemical data and product-specific clinical or in vitro evidence where formulation differences affect safety or performance. [3,4]

Orange Book status

The Orange Book is the controlling source for current listed patents, exclusivity, and reference-product information. Historical Corlopam listings and current fenoldopam products should be reviewed by application number and sponsor because product ownership and marketing status can change.

An Orange Book review should capture:

1. Listed patents for the reference product.
2. Patent expiration and pediatric-exclusivity dates.
3. Whether patents are formulation, method-of-use, or drug-substance claims.
4. Whether the reference product remains eligible for ANDA referencing.
5. Whether the listed product is discontinued for commercial reasons or withdrawn for safety or efficacy reasons.

No biosimilar pathway applies. Fenoldopam is a chemically synthesized small molecule, so competing products would use the generic-drug pathway rather than a 351(k) biosimilar application.

When does Corlopam lose exclusivity?

Corlopam’s original FDA exclusivity has expired. The original 1997 approval does not create a current barrier to generic development.

Protection type	Corlopam position
New chemical entity exclusivity	Expired
Original approval exclusivity	Expired
Biosimilar exclusivity	Not applicable
Potential listed patents	Must be confirmed in the current Orange Book
New formulation patents	Potentially available for novel products
Method-of-use patents	Potentially available for new, non-obvious uses
Device or packaging patents	Potentially available
Trade-secret protection	Available for manufacturing and control processes

A new patent estate could be built around a sulfite-free composition, a stable ready-to-use infusion, a defined oxygen-control package, a prefilled delivery system, or a new use supported by clinical evidence. Broad claims to fenoldopam itself would face serious prior-art and patent-term limitations.

What formulation patents could protect a new fenoldopam product?

The strongest patent claims would be narrow, data-supported claims linked to measurable technical effects.

Potential composition claims

A formulation patent could claim:

• Fenoldopam mesylate at a defined concentration range
• A specified antioxidant system
• A defined pH range
• A chelator-antioxidant combination
• Reduced dissolved oxygen
• A sulfite-free composition
• Stability after dilution in a specified infusion solution
• Limits on specified degradation products
• A particular ionic strength or buffer system

A composition claim is stronger when the formulation produces an unexpected stability advantage or solves a recognized clinical limitation. A generic claim covering any aqueous fenoldopam solution would face greater validity risk.

Potential packaging claims

Packaging claims could cover:

• Oxygen-impermeable multilayer bags
• Nitrogen or inert-gas headspace
• Light-protective overwrap
• Prefilled syringes with compatible elastomers
• Container closures that limit adsorption or leachables
• Dual-chamber systems that separate fenoldopam from diluent

Packaging patents may be commercially valuable because they can be difficult to design around when the product requires a specific stability profile over its labeled shelf life.

Potential method-of-use claims

Potential method-of-use opportunities include new acute-care settings, defined patient populations, or use with a specific infusion protocol. These claims would require clinical support and could be difficult to enforce where the label does not require the patented use.

A new method claim is more commercially useful if the use is likely to appear in hospital protocols and if competing products would be marketed for the same indication. Off-label prescribing can limit the practical value of method-of-use patents.

What manufacturing and IP barriers affect fenoldopam?

Fenoldopam development has several technical barriers even though the active ingredient is an established small molecule.

Oxidative degradation

The antioxidant system, oxygen exposure, pH, light, temperature, and trace metals can affect product stability. A robust program should map degradation pathways and identify the critical formulation variables before selecting excipients.

Sterile manufacturing

The product requires aseptic processing or validated terminal sterilization where feasible. The selected excipients must be compatible with sterilization, filtration, filling equipment, and container closures.

Container compatibility

A formulation that is chemically stable in a vial may behave differently in a syringe, infusion bag, or administration set. Adsorption, extractables, leachables, and loss of potency during infusion can create regulatory deficiencies and commercial complaints.

Dilution and in-use stability

The product must remain within specifications after dilution in hospital-use solutions. The label should provide clear limits for concentration, storage time, temperature, light exposure, and administration materials.

Supply chain

Sodium metabisulfite is inexpensive and widely available. The cost advantage of the existing excipient system means that a sulfite-free product must deliver a practical clinical or workflow benefit. More expensive antioxidants, specialized bags, or oxygen-control manufacturing can erode margins unless the product earns preferred formulary status.

What commercial opportunities exist for Corlopam alternatives?

The opportunity is concentrated in hospital injectable products rather than chronic outpatient therapy.

Hospital-ready formulation

A ready-to-use infusion could compete on:

• Lower pharmacy labor
• Reduced dilution errors
• Faster treatment initiation
• Lower preparation waste
• Easier barcode scanning
• Better standardization in emergency departments and intensive-care units

This is likely the broadest commercial opportunity.

Sulfite-sensitive patient positioning

A sulfite-free product could target hospitals seeking an alternative for patients with documented sulfite sensitivity. The addressable volume would be smaller, but the product could command a premium if supported by clear labeling and procurement value.

Shortage mitigation

Fenoldopam has a limited acute-care market, but injectable shortages can create procurement opportunities. A second-source manufacturer with reliable supply, dual-site manufacturing, and a ready-to-use presentation could win institutional contracts even without a major formulation change.

Contract manufacturing and licensing

Potential licensing targets include:

• An established generic injectable manufacturer lacking a fenoldopam product
• A hospital-focused specialty pharmaceutical company
• A prefilled-syringe or infusion-bag platform company
• A manufacturer with sterile fill-finish capacity
• A company holding an antioxidant or oxygen-control formulation platform

A licensing deal would be strongest where the formulation patent, FDA-ready development package, and manufacturing process are combined. A standalone patent without reliable sterile manufacturing would have limited transaction value.

How does Corlopam compare with competing antihypertensive injectables?

Fenoldopam competes clinically with several intravenous antihypertensive agents, including nicardipine, clevidipine, nitroprusside, labetalol, and esmolol. These products differ in mechanism, onset, titration, formulation, and hospital familiarity.

Product	Active ingredient	Common formulation characteristic	Competitive implication
Corlopam	Fenoldopam mesylate	Concentrated aqueous injection with antioxidant	Opportunity for ready-to-use and sulfite-free reformulation
Cardene	Nicardipine hydrochloride	Diluted IV infusion	Established hospital alternative
Cleviprex	Clevidipine	Lipid emulsion	Strong formulation differentiation but higher complexity
Nitropress	Sodium nitroprusside	IV solution requiring light protection	Competes in severe hypertension but has distinct toxicity concerns
Trandate and generics	Labetalol	Injectable solution	Familiar, broad hospital use
Brevibloc and generics	Esmolol	Injectable solution or premix	Useful where heart-rate control is also needed

Fenoldopam’s differentiation is its dopamine-1 agonism and renal vasodilatory profile. Its commercial weakness is lower routine utilization relative to established agents. A new product therefore needs a concrete operational advantage, such as premixing, improved stability, or easier emergency use.

Which generic launch scenarios are most plausible?

Scenario 1: Conventional generic concentrate

A manufacturer launches a vial matching the reference strength and core inactive-ingredient profile. This is the lowest-risk development path but likely has limited pricing power and weak differentiation.

Scenario 2: Ready-to-use infusion

A manufacturer develops a stable premix in a bag or syringe. This path has greater formulation and packaging work but creates a stronger hospital value proposition.

Scenario 3: Sulfite-free injection

A manufacturer replaces sodium metabisulfite with an alternative stabilization strategy. This path offers clinical differentiation but carries the highest formulation-development and regulatory risk.

Scenario 4: Specialty hospital product

A company markets a reliable fenoldopam product through hospital contracts, shortage-prevention programs, and critical-care distribution. The principal asset is supply reliability rather than patent exclusivity.

How strong is the patent estate for a new Corlopam formulation?

The legacy patent estate is unlikely to provide meaningful blocking protection for a new entrant because the product was approved in 1997 and the original exclusivity period has expired. A new patent estate could be moderate to strong if it includes:

• A non-obvious sulfite-free stabilization system
• Long-term stability data
• Defined impurity controls
• Container-closure limitations
• In-use infusion stability
• A commercially adopted ready-to-use presentation
• Manufacturing controls that are difficult to replicate

Patent strength would be weaker for claims covering only routine excipient substitutions, standard antioxidant use, or conventional infusion packaging. Regulatory exclusivity may offer limited additional protection, so commercial success would depend on differentiated performance, procurement access, and manufacturing reliability.

Key Takeaways

• Corlopam is fenoldopam mesylate injection, approved in 1997 for short-term blood-pressure reduction in severe hypertension.
• The reference formulation is an aqueous concentrate using sodium metabisulfite as an antioxidant.
• The strongest reformulation opportunity is a ready-to-use infusion that reduces dilution and preparation steps.
• A sulfite-free product offers clinical differentiation but requires substantial stability and compatibility work.
• Fenoldopam has no biosimilar pathway because it is a synthetic small molecule.
• Original drug exclusivity has expired; current Orange Book listings must be reviewed for any remaining listed patents.
• New protection is most plausible for formulation, packaging, in-use stability, manufacturing, and delivery-system claims.
• Competitive pressure comes from nicardipine, clevidipine, nitroprusside, labetalol, and esmolol injectables.
• The commercial market is specialized and hospital-based. Supply reliability and workflow benefits are likely to matter more than broad price competition.
• A licensing package combining formulation IP, sterile manufacturing capability, and an FDA-ready development file would have the strongest commercial value.

FAQs

Is Corlopam the same as fenoldopam?

Yes. Corlopam is the brand name for fenoldopam mesylate injection.

Does Corlopam contain sodium metabisulfite?

The reference product labeling identifies sodium metabisulfite as an inactive ingredient and antioxidant. [1]

Can a company patent a sulfite-free fenoldopam injection?

Potentially, if the formulation is novel, non-obvious, and supported by stability and performance data. A routine substitution of one antioxidant for another would face greater patentability risk.

Is fenoldopam eligible for a biosimilar application?

No. Fenoldopam is a synthetic small molecule and would generally be developed through the generic-drug pathway rather than the biosimilar pathway.

What is the best commercial presentation for a new fenoldopam product?

A ready-to-use, preservative-free infusion with validated room-temperature and in-use stability would likely offer the clearest hospital differentiation over a conventional concentrate.

References

1. U.S. Food and Drug Administration. (1997). Corlopam (fenoldopam mesylate) injection prescribing information. FDA.
2. National Library of Medicine. (n.d.). Corlopam: Fenoldopam mesylate injection, solution. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2017). ANDAs for certain highly purified synthetic peptides: Development and submission considerations. FDA.